Hepatitis B
616
30
43
411
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
142 trials with published results (23%)
Research Maturity
411 completed trials (67% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.2%
38 terminated out of 616 trials
91.5%
+4.9% vs benchmark
38%
235 trials in Phase 3/4
35%
142 of 411 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 411 completed trials
Clinical Trials (616)
Evaluation of Patients With Liver Disease
National Liver Cancer Screening Trial
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver
Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
Study of BK1803 in Healthy Infants
Strengthening, Guidance, Health, Empowerment
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease